Ranibizumab versus verteporfin for neovascular age-related macular degeneration.
暂无分享,去创建一个
Susan Schneider | Mark Michels | J. P. Sy | Peter K Kaiser | P. Kaiser | G. Soubrane | J. Sy | J. Heier | David M. Brown | S. Schneider | Jeffrey S Heier | David M Brown | Gisele Soubrane | R. Kim | Robert Y Kim | Judy P Sy | M. Michels
[1] Usha Chakravarthy,et al. Morphometric analysis of angiograms of exudative lesions in age-related macular degeneration. , 2004, Archives of ophthalmology.
[2] Z. Tomić,et al. [Photodynamic therapy of subfoveal choroidal neovascularization]. , 2007, Srpski arhiv za celokupno lekarstvo.
[3] N. Bressler,et al. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. , 1999, Archives of ophthalmology.
[4] P. Jong. Prevalence of age-related macular degeneration in the United States. , 2004 .
[5] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[6] S. Resnikoff,et al. Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.
[7] Robert W. Massof,et al. Racial variations in causes of vision loss in nursing homes: The Salisbury Eye Evaluation in Nursing Home Groups (SEEING) Study. , 2004, Archives of ophthalmology.
[8] Benita J. O’Colmain,et al. Prevalence of age-related macular degeneration in the United States. , 2004, Archives of ophthalmology.
[9] D. Pauleikhoff,et al. NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Natural History and Treatment Outcomes , 2005, Retina.
[10] T. Ciulla,et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. , 2006, Archives of ophthalmology.
[11] Verteporfin Roundtable Participants. GUIDELINES FOR USING VERTEPORFIN (VISUDYNE®) IN PHOTODYNAMIC THERAPY TO TREAT CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES , 2002, Retina.
[12] Phillip G Yuile,et al. Age‐related macular degeneration: a leading cause of blindness , 1997, The Medical journal of Australia.
[13] Philip J Rosenfeld,et al. Ranibizumab for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[14] F. Ferris,et al. Age-related macular degeneration and blindness due to neovascular maculopathy. , 1984, Archives of ophthalmology.
[15] N. Bressler. GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATE , 2005, Retina.
[16] E. Gragoudas,et al. Pegaptanib for neovascular age-related macular degeneration. , 2004, The New England journal of medicine.
[17] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[18] J. Jonas. VERTEPORFIN THERAPY OF SUBFOVEAL CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: Meta-Analysis of 2-Year Safety Results in Three Randomized Clinical Trials: Treatment of Age-Related Macular Degeneration with Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Report , 2002, American journal of ophthalmology.
[19] N. Bressler. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. , 2001 .
[20] A. Fletcher,et al. Methods for a population-based study of the prevalence of and risk factors for age-related maculopathy and macular degeneration in elderly European populations: the EUREYE study , 2004, Ophthalmic epidemiology.
[21] W. G. Cochran. Some Methods for Strengthening the Common χ 2 Tests , 1954 .
[22] Walker,et al. Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .